Dennis E. Hruby, Ph.D., serves as the Executive Vice President and Chief Scientific Officer at SIGA Technologies Inc., a position he has held since joining the company. With a robust background in virology and molecular biology, Dr. Hruby has been instrumental in steering the scientific direction of SIGA Technologies, a company focused on developing and commercializing solutions for biodefense and emerging infectious diseases. His leadership has been pivotal in advancing the company's portfolio, particularly in the development of antiviral therapeutics. Prior to his role at SIGA Technologies, Dr. Hruby held various academic and research positions that have shaped his expertise in the field. He earned his Ph.D. in Biochemistry from the University of California, Riverside, and subsequently conducted postdoctoral research at the University of California, San Diego. Dr. Hruby's career also includes a significant tenure as a professor and researcher at Oregon State University, where he led numerous studies on poxviruses, which have been foundational to his work at SIGA. His contributions to the scientific community are evidenced by his numerous publications and patents, which have advanced the understanding and treatment of viral diseases. At SIGA Technologies, Dr. Hruby oversees the research and development efforts, ensuring that the company remains at the forefront of innovation in antiviral drug discovery. His strategic vision has been crucial in the development of TPOXX (tecovirimat), a smallpox antiviral drug approved by the FDA, which represents a significant achievement in biodefense. Under his guidance, SIGA continues to explore new avenues for combating infectious diseases, leveraging his extensive knowledge and experience to drive the company's mission forward.